Immune responses and bone loss: The estrogen connection

Immunological Reviews

Volumn 208, Issue , 2005, Pages 194-206

  Carlsten, Hans ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; CORTICOSTEROID; DEXAMETHASONE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GENISTEIN; IMMUNOGLOBULIN; NANDROLONE; PROGESTERONE; RALOXIFENE; TAMOXIFEN;

B LYMPHOCYTE; BREAST CANCER; CANCER RISK; DOWN REGULATION; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FREQUENCY ANALYSIS; HORMONE SUBSTITUTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; ISCHEMIC HEART DISEASE; JOINT DESTRUCTION; LYMPHOPOIESIS; MENOPAUSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOSIS; UPREGULATION;

EID: 28544436162     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00326.x     Document Type: Review

References (95)

1. Matthews J, Gustafsson JA. Estrogen signal-ing: a subtle balance between ER alpha and ER beta. Mol Interv 2003;3:281-292.
2. Hewitt SC, Harrell JC, Korach KS. Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 2005;67:285-308.
3. Prelevic GM, Kocjan T, Markou A. Hormone replacement therapy in postmenopausal women. Minerva Endocrinol 2005;30:27-36.
4. Offner H, Adlard K, Zamora A, Vandenbark AA. Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis. J Clin Invest 2000;105:1465-1472.
5. Jansson L, Holmdahl R. Oestrogen induced suppression of collagen arthritis. IV. Progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. J Reprod Immunol 1989;15:141-150.
6. Voskuhl RR. Hormone-based therapies in MS. Int MS J 2003;10:60-66.
7. Forsblad d'Elia H, et al. Influence of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003;30:1456-1463.
8. Holmdahl R, Bockermann R, Backlund J, Yamada H. The molecular pathogenesis of collagen-induced arthritis in mice-a model for rheumatoid arthritis. Ageing Res Rev 2002;1:135-147.
9. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002;61 (Suppl.):ii84-86.
10. Haugeberg G, Orstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol 2003;15:469-475.
11. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002;23:90-119.
12. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999;20:435-459.
13. Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005;19:833-842.
14. Lorenzo J. A new hypothesis for how sex steroid hormones regulate bone mass. J Clin Invest 2003;111:1641-1643.
15. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005;307:1625-1630.
16. Holmdahl R, Carlsten H, Jansson L, Larsson P. Oestrogen is a potent immunomodulator of murine experimental rheumatoid disease. Br J Rheumatol 1989;28 (Suppl.):54-58; Discussion 69-71.
17. Grossman CJ, Roselle GA, Mendenhall CL. Sex steroid regulation of autoimmunity. J Steroid Biochem Mol Biol 1991;40:649-659.
18. Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update 2005;11:411-423.
19. Savino W, Dardenne M. Neuroendocrine control of thymus physiology. Endocr Rev 2000;21:412-443.
20. Staples JE, Gasiewicz TA, Fiore NC, Lubahn DB, Korach KS, Silverstone AE. Estrogen receptor alpha is necessary in thymic development and estradiol-induced thymic alterations. J Immunol 1999;163:4168-4174.
21. Erlandsson MC, Ohlsson C, Gustafsson JA, Carlsten H. Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus. Immunology 2001;103:17-25.
22. Lindberg MK, et al. Estrogen receptor specificity for the effects of estrogen in ovariectomized mice. J Endocrinol 2002;174:167-178.
23. Islander U, et al. Estren-mediated inhibition of T lymphopoiesis is estrogen receptor-independent whereas its suppression of T cell-mediated inflammation is estrogen receptor-dependent. Clin Exp Immunol 2005;139:210-215.
24. Savino W, Smaniotto S, Binart N, Postel-Vinay MC, Dardenne M. In vivo effects of growth hormone on thymic cells. Ann NY Acad Sci 2003;992:179-185.
25. Islander U, et al. Influence of oestrogen receptor alpha and beta on the immune system in aged female mice. Immunology 2003;110:149-157.
26. Kincade PW, Medina KL, Smithson G. Sex hormones as negative regulators of lymphopoiesis. Immunol Rev 1994;137:119-134.
27. Thurmond TS, Murante FG, Staples JE, Silverstone AE, Korach KS, Gasiewicz TA. Role of estrogen receptor alpha in hematopoietic stem cell development and B lymphocyte maturation in the male mouse. Endocrinology 2000;141:2309-2318.
28. Erlandsson MC, Jonsson CA, Lindberg MK, Ohlsson C, Carlsten H. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol 2002;175:319-327.
29. Erlandsson MC, Jonsson CA, Islander U, Ohlsson C, Carlsten H. Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice. Immunology 2003;108:346-351.
30. Kincade PW, et al. Early B-lymphocyte precursors and their regulation by sex steroids. Immunol Rev 2000;175:128-137.
31. Smithson G, Couse JF, Lubahn DB, Korach KS, Kincade PW. The role of estrogen receptors and androgen receptors in sex steroid regulation of B lymphopoiesis. J Immunol 1998;161:27-34.
32. Benten WP, Stephan C, Wunderlich F. B cells express intracellular but not surface receptors for testosterone and estradiol. Steroids 2002;67:647-654.
33. Josefsson E, Tarkowski A, Carlsten H. Anti-inflammatory properties of oestrogen: in vivo suppression of leucocyte production in bone-marrow and redistribution of peripheral neutrophils. Cell Immunol 1992;142:67-78.
34. Carlsten H, Holmdahl R, Tarkowski A, Nilsson LA. Oestradiol- and testosterone-mediated effects on the immune system in normal and autoimmune mice are genetically linked and inherited as dominant traits. Immunology 1989;68:209-214.
35. Carlsten H, Holmdahl R, Tarkowski A, Nilsson LA. Oestradiol suppression of delayed-type hypersensitivity in autoimmune (NZB/NZW) F1 mice is a trait inherited from the healthy NZW parental strain. Immunology 1989;67:205-209.
36. Carlsten H, Holmdahl R, Tarkowski A. Analysis of the genetic encoding of oestradiol suppression of delayed-type hypersensitivity in (NZB x NZW) F1 mice. Immunology 1991;73:186-190.
37. Nilsson N, Carlsten H. Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation. Cell Immunol 1994;158:131-139.
38. Carlsten H, Verdrengh M, Taube M. Additive effects of suboptimal doses of estrogen and cortisone on the suppression of T lymphocyte dependent inflammatory responses in mice. Inflamm Res 1996;45:26-30.
39. Erlandsson M, Jonsson CA, Islander U, Ohlsson C, Carlsten H. Oestrogen receptor specificity in oestradiol-mediated effects on B lymphopoiesis and immunoglobulin production in male mice. Immunology 2003;108:346-351.
40. Griffith JS, et al. Evidence for the genetic control of estradiol-regulated responses. Implications for variation in normal and pathological hormone-dependent phenotypes. Am J Pathol 1997;150:2223-2230.
41. Roper RJ, et al. Interacting quantitative trait loci control phenotypic variation in murine estradiol-regulated responses. Endocrinology 1999;140:556-561.
42. Maret A, et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur J Immunol 2003;33:512-521.
43. Fox HS, Bond BL, Parslow TG. Estrogen regulates the IFN-gamma promoter. J Immunol 1991;146:4362-4367.
44. Rubanyi GM, Johns A, Kauser K. Effect of estrogen on endothelial function and angiogenesis. Vascul Pharmacol 2002;38:89-98.
45. Hisamoto K, Bender JR. Vascular cell signaling by membrane estrogen receptors. Steroids 2005;70:382-387.
46. Simoncini T, et al. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 2004;69:537-542.
47. Hanna N, Schneider M. Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment. J Immunol 1983;130:974-980.
48. Taube M, Carlsten H. Action of dexamethasone in the suppression of delayed-type hypersensitivity in reconstituted SCID mice. Inflamm Res 2000;49:548-552.
49. Compston JE. Sex steroids and bone. Physiol Rev 2001;81:419-447.
50. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004;25:389-425.
51. Lombardi G, et al. Estrogens and health in males. Mol Cell Endocrinol 2001;178:51-55.
52. Girasole G, et al. 17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992;89:883-891.
53. Forsblad d'Elia H, Mattsson LA, Ohlsson C, Nordborg E, Carlsten H. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. Arthritis Res Ther 2003;5:R202-R209.
54. Bellido T, et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 1995;95:2886-2895.
55. Pottratz ST, Bellido T, Mocharla H, Crabb D, Manolagas SC. 17 beta-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest 1994;93:944-950.
56. Pacifici R, Vannice JL, Rifas L, Kimble RB. Monocytic secretion of interleukin-1 receptor antagonist in normal and osteoporotic women: effects of menopause and estrogen/ progesterone therapy. J Clin Endocrinol Metab 1993;77:1135-1141.
57. Cenci S, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000;106:1229-1237.
58. Roggia C, et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001;98:13960-13965.
59. Cenci S, et al. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003;100:10405-10410.
60. Taube M, Svensson L, Carlsten H. T lymphocytes are not the target for estradiol-mediated suppression of DTH in reconstituted female severe combined immunodeficient (SCID) mice. Clin Exp Immunol 1998;114:147-153.
61. Miyaura C, et al. Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency. Proc Natl Acad Sci USA 1997;94:9360-9365.
62. Lindberg M, et al. Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss. Bone (in press).
63. Ciana P, et al. In vivo imaging of transcriptionally active estrogen receptors. Nat Med 2003;9:82-86.
64. Andersson N, et al. Investigation of central versus peripheral effects of estradiol in ovariectomized mice. J Endocrinol (in press).
65. Erlandsson MC, Gomori E, Taube M, Carlsten H. Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. Cell Immunol 2000;205:103-109.
66. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, Karathanasis SK. The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells. Endocrinology 2000;141:3403-3411.
67. Chen A, Rogan WJ. Isoflavones in soy infant formula: a review of evidence for endocrine and other activity in infants. Annu Rev Nutr 2004;24:33-54.
68. Yellayi S, et al. The phytoestrogen genistein induces thymic and immune changes: a human health concern? Proc Natl Acad Sci USA 2002;99:7616-7621.
69. Ishimi Y, et al. Difference in effective dosage of genistein on bone and uterus in ovariectomized mice. Biochem Biophys Res Commun 2000;274:697-701.
70. Erlandsson MC, Islander U, Moverare S, Ohlsson C, Carlsten H. Estrogenic agonism and antagonism of the soy isoflovaone genistein in uterus, bone and lymphopoiesis in mice. APMIS 2005;113:317-323.
71. Kousteni S, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001;104:719-730.
72. Kousteni S, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 2002;298:843-846.
73. Kousteni S, et al. Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. J Clin Invest 2003;111:1651-1664.
74. Moverare S, et al. Estren is a selective estrogen receptor modulator with transcriptional activity. Mol Pharmacol 2003;64:1428-1433.
75. Centrella M, McCarthy TL, Chang WZ, Labaree DC, Hochberg RB. Estren (4-estre-n-3alpha,17beta-diol) is a prohormone that regulates both androgenic and estrogenic transcriptional effects through the androgen receptor. Mol Endocrinol 2004;18:1120-1130.
76. Islander U, et al. Estren promotes androgen phenotype in primary lymphoid organs and submandibular glands. BMC Immunol 2005;6:16.
77. Krishnan V, et al. The nongenotropic synthetic ligand 4-estren-3alpha17beta-diol is a high-affinity genotropic androgen receptor agonist. Mol Pharmacol 2005;67:744-748.
78. Lindberg MK, Alatalo SL, Halleen JM, Mohan S, Gustafsson JA, Ohlsson C. Estrogen receptor pecificity in the regulation of the skeleton in female mice. J Endocrinol 2001;171:229-236.
79. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol 1985;37:269-390.
80. Steinberg AD, et al. Approach to the study of the role of sex hormones in autoimmunity. Arthritis Rheum 1979;22:1170-1176.
81. Carlsten H, Tarkowski A. Histocompatibility complex gene products and exposure to oestrogen: two independent disease accelerating factors in murine lupus. Scand J Immunol 1993;38:341-347.
82. Carlsten H, Tarkowski A, Jonsson R, Nilsson LA. Expression of heterozygous lpr gene in MRL mice. II. Acceleration of glomerulonephritis, sialadenitis, and autoantibody production. Scand J Immunol 1990;32:21-28.
83. Steinberg AD, Roths JB, Murphy ED, Steinberg RT, Raveche ES. Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice. J Immunol 1980;125:871-873.
84. Carlsten H, Nilsson N, Jonsson R, Backman K, Holmdahl R, Tarkowski A. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice. Cell Immunol 1992;144:190-202.
85. Carlsten H, Nilsson N, Jonsson R, Tarkowski A. Differential effects of oestrogen in murine lupus: acceleration of glomerulonephritis and amelioration of T cell-mediated lesions. J Autoimmun 1991;4:845-856.
86. Ahmed AS, Aufdemorte TB, Chen J-R, Montoya AI, Olive D, Talal N. Estrogen induces the development of autoantibodies and promotes salivary gland lympfoid infiltrates in normal mice. J Autoimmunity 1989;2:543-552.
87. McMurray R, Keisler D, Kanuckel K, Izui S, Walker SE. Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991;147:3780-3787.
88. Grimaldi CM, Hill L, Xu X, Peeva E, Diamond B. Hormonal modulation of B cell development and repertoire selection. Mol Immunol 2005;42:811-820.
89. Jochems C, Islander U, Erlandsson MC, Verdrengh M, Ohlsson C, Carlsten H. Osteoporosis in experimental postmenopausal polyarthritis: relative contributions of estrogen deficiency and inflammation. Arthritis Res Ther 2005;7:837-843.
90. Forsblad D'Elia H, et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003;62:617-623.
91. Jansson L, Holmdahl R. Enhancement of collagen-induced arthritis in female mice by estrogen receptor blockage. Arthritis Rheum 2001;44:2168-2175.
92. Hall GM, Daniels M, Huskisson EC, Spector TD. A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 1994;53:112-116.
93. MacDonald AG, Murphy EA, Capell HA, Bankowska UZ, Ralston SH. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 1994;53:54-57.
94. Forsblad d'Elia H, et al. The impact of hormone replacement therapy on disease progression and bone mineral density in rheumatoid arthritis. J Rheumatol 2003;30:1456-1463.
95. Forsblad d'Elia H, et al. Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]. Arthritis Res Ther 2004;6:R457-R468.